IP Library Granted Patent US 12,168,040
Granted Patent B2
US 12,168,040 · App. 17/168,971 · Granted Dec 17, 2024

Sequence specific antimicrobials

Inventors: David Bikard (Paris, FR); Luciano Marraffini (Brooklyn, NY)
Assignee: The Rockefeller University
A61K38/465A01N63/00A61K31/7105A61K31/713A61K45/06C12N9/16C12N9/22C12N15/113C12N15/74C12Y301/00C12N2310/10C12N2310/20C12N2795/10331C12N2795/10332C12N2795/10343C12N2795/10371
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,168,040
App. No.
17/168,971
Granted
Dec 17, 2024
Kind
B2
Abstract

Provided are compositions and methods for selectively reducing the amount of antibiotic resistant and/or virulent bacteria in a mixed bacteria population, or for reducing any other type of unwanted bacteria in a mixed bacteria population. The compositions and methods involve targeting bacteria that are differentiated from other members of the population by at least one unique clustered regularly interspaced short palindromic repeats (CRISPR) targeted DNA sequence. The compositions and methods can be readily adapted to target any bacteria or any bacteria plasmid, or both.

Claims (16)

1. A method comprising:

exposing a microbiota in a human patient to an antimicrobial agent to selectively kill cells of a first bacterial species in the microbiota,

wherein selectively killing the cells of the first bacterial species is carried out by cutting a target site comprised by the genomes of the first bacterial species,

wherein the cutting is carried out using a Cas nuclease of a Type I, Type II, or Type III CRISPR system that cleaves the target site; and

wherein the selective killing is carried out by avoiding killing second cells comprised by the microbiota, wherein the second cells are of a different strain or a different species from the cells of the first bacterial species.

2. The method of claim 1 , wherein the cells of the first bacterial species and the second cells are comprised by a skin microbiota.

3. The method of claim 1 , wherein the target site is in an immune response inhibitor.

4. The method of claim 1 , wherein the targeted bacteria is a Staphylococcus.

5. The method of claim 1 , wherein the targeted bacteria is a Mycobacterium.

6. The method of claim 1 , wherein the targeted bacteria is a Pseudomonas.

7. The method of claim 1 , wherein the Cas nuclease is a Cas nuclease of the type II CRISPR system.

8. The method of claim 7 , wherein the Cas nuclease is a Cas9.

9. The method of claim 8 , wherein the first bacteria are Staphylococcus aureus.

10. The method of claim 7 , wherein the first bacteria are Staphylococcus aureus.

11. The method of claim 10 , wherein the first bacteria are a methicillin-resistant Staphylococcus aureus.

12. The method of claim 9 , wherein the first bacteria are a methicillin-resistant Staphylococcus aureus.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 30, 2024
From: BIKARD, DAVID
To: THE ROCKEFELLER UNIVERSITY
Reel/Frame 069081/0582 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 30, 2024
From: MARRAFFINI, LUCIANO
To: THE ROCKEFELLER UNIVERSITY
Reel/Frame 069081/0590 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 30, 2024
From: MARRAFFINI, LUCIANO
To: THE ROCKEFELLER UNIVERSITY
Reel/Frame 069081/0606 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 30, 2024
From: BIKARD, DAVID
To: THE ROCKEFELLER UNIVERSITY
Reel/Frame 069081/0625 →
Continuity (8)
Division 16877010 · May 18, 2020
Division 16877030 · May 18, 2020
Division 15159929 · May 20, 2016
Division 15159929 · May 20, 2016
Continuation 14766675
Division 14766675
Provisional Application 61761971 · Feb 7, 2013
Related Publication 20210162022A1 · Jun 3, 2021